141 related articles for article (PubMed ID: 9572231)
1. Chemotherapy resistance in ovarian cancer: new molecular perspectives.
Coukos G; Rubin SC
Obstet Gynecol; 1998 May; 91(5 Pt 1):783-92. PubMed ID: 9572231
[TBL] [Abstract][Full Text] [Related]
2. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
5. p53 gene status and chemosensitivity in ovarian cancer.
Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
7. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
Ong PS; Chan SY; Ho PC
Eur J Pharm Sci; 2012 Feb; 45(3):367-78. PubMed ID: 22178533
[TBL] [Abstract][Full Text] [Related]
8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.
Poulain L; Lincet H; Duigou F; Deslandes E; Sichel F; Gauduchon P; Staedel C
Int J Cancer; 1998 Nov; 78(4):454-63. PubMed ID: 9797134
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in ovarian cancer: from the laboratory to the clinic.
Sood AK; Buller RE
Obstet Gynecol; 1998 Aug; 92(2):312-9. PubMed ID: 9699774
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract][Full Text] [Related]
13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.
Takahashi M; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Akeshima R; Terakawa N
Eur J Cancer; 2000 Sep; 36(14):1863-8. PubMed ID: 10974635
[TBL] [Abstract][Full Text] [Related]
16. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
19. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.
L'Espérance S; Bachvarova M; Tetu B; Mes-Masson AM; Bachvarov D
BMC Genomics; 2008 Feb; 9():99. PubMed ID: 18302766
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
